Correction to: Diabetes Ther https://doi.org/10.1007/s13300-020-00815-z
In the original article, Table 1 was published with a type-set error. The correct Table 1 is given below.
Table 1
Demographics and baseline characteristics for participants with Type 2 diabetes, by baseline CKD category—8-study pool (intention-to-treat analysis set)
Characteristic | CKD3 | CKD2 | ||
|---|---|---|---|---|
EQW N = 182 | All comparators N = 207 | EQW N = 772 | All comparators N = 1043 | |
Men, n (%) | 105 (57.7) | 105 (50.7) | 419 (54.3) | 608 (58.3) |
Age (years), mean (SD) | 62.5 (9.0) | 62.2 (9.0) | 56.9 (9.3) | 56.9 (9.5) |
Age < 65 years, n(%) | 102 (56.0) | 120 (58.0) | 613 (79.4) | 820 (78.6) |
Race, White, n (%) | 66 (36.3) | 89 (43.0) | 522 (67.6) | 685 (65.7) |
Race, Asian, n (%) | 111 (61.0) | 106 (51.2) | 157 (20.3) | 227 (21.8) |
Race, Black or African American, n (%) | 0 | 5 (2.4) | 38 (4.9) | 39 (3.7) |
Body weight (kg), mean (SD) | 76.9 (19.3) | 78.5 (17.7) | 88.8 (19.3)a | 87.8 (19.1) |
BMI (kg/m2), mean (SD) | 28.3 (5.1) | 29.6 (5.8) | 31.6 (5.5)a | 31.4 (5.6) |
BMI ≥ 35 (kg/m2), n (%) | 24 (13.2) | 40 (19.3) | 196 (25.4) | 246 (23.6) |
Sitting SBP (mm Hg), mean (SD) | 133 (14.3) | 136 (17.2) | 131 (13.8) | 131 (14.6) |
Sitting DBP (mm Hg), mean (SD) | 77 (9.7) | 79 (9.6) | 79 (9.3) | 79 (8.8) |
eGFR (mL/min/1.73 m2), mean (SD) | 52.7 (5.6) | 53.3 (5.1) | 75.9 (8.4) | 75.9 (8.6) |
uACR (mg/g), mean (SD), median | 105 (348), 14.2 (n = 151) | 116 (438), 20.4 (n = 165) | 54.1 (171), 10.6 (n = 528) | 47.9 (158), 10.6 (n = 810) |
< 30 mg/g (normal), n (%) | 96 (52.7) | 108 (52.2) | 398 (51.6) | 609 (58.4) |
≥ 30 to ≤ 300 mg/g (moderately increased albuminuria), n (%) | 45 (24.7) | 46 (22.2) | 108 (14.0) | 178 (17.1) |
> 300 mg/g (severely increased albuminuria), n (%) | 10 (5.5) | 11 (5.3) | 22 (2.8) | 23 (2.2) |
Unknownb, n (%) | 31 (17.0) | 42 (20.3) | 244 (31.6) | 233 (22.3) |
Duration of T2D (years), mean (SD) | 9.7 (6.8) | 9.5 (6.8) | 7.6 (6.3)a | 6.3 (5.5)a |
HbA1c (%), mean (SD) | 8.3 (0.8) | 8.5 (0.9) | 8.5 (1.1) | 8.4 (1.1) |
FPG (mg/dL), mean (SD) | 168 (46.7) (n = 181) | 176 (50.2) (n = 203) | 172 (50.0) (n = 751) | 171 (46.8) (n = 1026) |
Baseline anti-hyperglycaemic drugsc | ||||
None, n (%) | 8 (4.4) | 34 (16.4) | 135 (17.5) | 299 (28.7) |
Metformin, n (%) | 155 (85.2) | 159 (72.5) | 529 (68.5) | 647 (62.0) |
Sulfonylureas, n (%) | 4 (2.2) | 10 (4.8) | 55 (7.1) | 55 (5.3) |
Thiazolidinediones, n (%) | 36 (19.8) | 31 (15.0) | 32 (4.1) | 39 (3.7) |
Insulin, n (%) | 18 (9.9) | 22 (10.6) | 107 (13.9) | 98 (9.4) |
The original article has been corrected.
Anzeige
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.